ArticleBMC cancer2025

CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer.

Alessandro Passardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.